Effects of flaxseed supplements on blood pressure: A systematic review and meta-analysis of controlled clinical trial

Authors:

Sorin Ursoniu |
Amirhossein Sahebkar |
Florina Andrica |
Corina Serban |
Maciej Banach |
Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group

First published: May 29, 2015 | https://doi.org/10.1016/j.clnu.2015.05.012

Abstract:

Background & aims

Many experimental and clinical trials suggested that flaxseed might be a potent antihypertensive, but the evidences concerning the effects of flaxseed supplements on blood pressure (BP) has not been fully conclusive. We aimed to assess the impact of the effects of flaxseed supplements on blood pressure through systematic review of literature and meta-analysis of available randomized controlled trials (RCTs).

Methods

The literature search included PUBMED, Cochrane Library, Scopus, and EMBASE up to February 2015 to identify RCTs investigating the effect of flaxseed supplements on plasma blood pressure. Effect size was expressed as weighed mean difference (WMD) and 95% confidence interval (CI).

Results

15 trials (comprising 19 treatment arms) with 1302 participants were included in this meta-analysis. Random-effects meta-analysis suggested significant reductions in both systolic BP (SBP) (WMD: −2.85 mmHg, 95%CI: −5.37 to −0.33, p = 0.027) and diastolic BP (DBP) (WMD: −2.39 mmHg, 95%CI: −3.78 to −0.99, p = 0.001) following supplementation with flaxseed products. When the studies were stratified according to their duration, there was a greater effect on both SBP and DBP in the subset of trials with ≥12 weeks of duration (WMD: −3.10 mmHg, 95%CI: −6.46 to 0.27, p = 0.072 and −2.62 mmHg, 95%CI: −4.39 to −0.86, p = 0.003, respectively) vs the subset lasting <12 weeks (WMD: −1.60 mmHg, 95%CI: −5.44 to 2.24, p = 0.413, and −1.74 mmHg, 95%CI: −4.41 to 0.93, p = 0.202, respectively). Another subgroup analysis was performed to assess the impact of flaxseed supplement type on BP. Reduction of SBP was significant with flaxseed powder (WMD: −1.81 mmHg, 95% CI: −2.03 to −1.59, p < 0.001) but not oil (WMD: −4.62 mmHg, 95%CI: −11.86 to 2.62, p = 0.211) and lignan extract (WMD: 0.28 mmHg, 95% CI: −3.49 to 4.04, p = 0.885). However, DBP was significantly reduced with powder and oil preparations (WMD: −1.28 mmHg, 95% CI: −2.44 to −0.11, p = 0.031, and −4.10 mmHg, 95%CI: −6.81 to −1.39, p = 0.003, respectively), but not with lignan extract (WMD: −1.78 mmHg, 95% CI: −4.28 to 0.72, p = 0.162).

Conclusions

This meta-analysis of RCTs showed significant reductions in both SBP and DBP following supplementation with various flaxseed products.

  1. Bazzano L.A., Green T., Harrison T.N., Reynolds K.
    Dietary approaches to prevent hypertension.
    Curr Hypertens Rep. 2013; 15: 694-702
  2. Pacheco J.T., Daleprame J.B., Boaventura G.T.
    Impact of dietary flaxseed (linum usitatissimum) supplementation on biochemical profile in healthy rats.
    Nutr Hosp. 2011; 26: 798-802
  3. Bassett C.M., McCullough R.S., Edel A.L., Patenaude A., LaVallee R.K., Pierce G.N.
    The α-linolenic acid content of flaxseed can prevent the atherogenic effects of dietary trans fat.
    Am J Physiol-Heart Circulat Physiol. 2011; 301: H2220-H2226
  4. Dupasquier C.M., Weber A.-M., Ander B.P., Rampersad P., Steigerwald S., Wigle J.T., et al.
    Effects of dietary flaxseed on vascular contractile function and atherosclerosis during prolonged hypercholesterolemia in rabbits.
    Am J Physiol-Heart Circulat Physiol. 2006; 291: H2987-H2996
  5. Dupasquier C.M., Dibrov E., Kneesh A.L., Cheung P.K.,Lee K.G., Alexander H.K., et al.
    Dietary flaxseed inhibits atherosclerosis in the LDL receptor-deficient mouse in part through antiproliferative and anti-inflammatory actions.
    Am J Physiol-Heart Circulat Physiol. 2007; 293: H2394-H2402
  6. Caligiuri S.P., Aukema H.M., Ravandi A., Pierce G.N.
    Elevated levels of pro-inflammatory oxylipins in older subjects are normalized by flaxseed consumption.
    Exp Gerontol. 2014; 59: 51-57
  7. Caligiuri S.P.B., Edel A.L., Aliani M., Pierce G.N.
    Flaxseed for hypertension: implications for blood pressure regulation.
    Curr Hypertens Rep. 2014; 16: 1-13
  8. Mazza G., Oomah B.D.
    Flaxseed n. flaxseed in human nutrition.
    1995
  9. Bloedon L.T., Szapary P.O.
    Flaxseed and cardiovascular risk.
    Nutr Rev. 2004; 62: 18-27
  10. Epaminondas P.S., Araújo K.L.G.V., de Souza A.L., Silva M.C.D., Queiroz N., Souza A.L., et al.
    Influence of toasting on the nutritious and thermal properties of flaxseed.
    J Therm Anal Calorim. 2011; 106: 551-555
  11. Sargi S.C., Silva B.C., Santos H.M.C., Montanher P.F., Boeing J.S., Santos Júnior O.O., et al.
    Antioxidant capacity and chemical composition in seeds rich in omega-3: chia, flax, and perilla.
    Food Sci Technol (Campinas). 2013; 33: 541-548
  12. Khalesi S., Irwin C., Schubert M.
    Flaxseed consumption may reduce blood pressure: a systematic review and meta-analysis of controlled trials.
    J Nutr. 2015; (jn. 114.205302)
  13. Whelton S.P., Hyre A.D., Pedersen B., Yi Y., Whelton P.K., He J.
    Effect of dietary fiber intake on blood pressure: a meta-analysis of randomized, controlled clinical trials.
    J Hypertens. 2005; 23: 475-481
  14. Streppel M.T., Arends L.R., van ‘t Veer P., Grobbee D.E., Geleijnse J.M.
    Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials.
    Arch Intern Med. 2005; 165: 150-156
  15. Moher D., Liberati A., Tetzlaff J., Altman D.G.
    Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
    BMJ. 2009; : 339
  16. Green S.
    Cochrane handbook for systematic reviews of interventions version 5.1.0.
    ([updated March 2011]) The Cochrane Collaboration, 2011
  17. Hozo S., Djulbegovic B., Hozo I.
    Estimating the mean and variance from the median, range, and the size of a sample.
    BMC Med Res Methodol. 2005; 5: 13
  18. Sahebkar A.
    Does PPARgamma2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis.
    DNA Cell Biol. 2013; 32: 188-198
  19. Sahebkar A.
    Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis.
    Phytother Res. 2014; 28: 633-642
  20. Duval S., Tweedie R.
    Trim and fill: a Simple funnel-plot-based method of testing and Adjusting for publication bias in meta-analysis.
    Biometrics. 2000; 56: 455-463
  21. Barden A.E., Croft K.D., Durand T., Guy A., Mueller M.J., Mori T.A.
    Flaxseed oil supplementation increases plasma F1-phytoprostanes in healthy men.
    J Nutr. 2009; 139: 1890-1895
  22. Barre D.E., Mizier-Barre K.A., Stelmach E., Hobson J., Griscti O., Rudiuk A., et al.
    Flaxseed lignan complex administration in older human type 2 diabetics manages central obesity and prothrombosis-an invitation to further investigation into polypharmacy reduction.
    J Nutr Metabolism. 2012; 2012: 585170
  23. Cornish S.M., Chilibeck P.D., Paus-Jennsen L., Biem H.J., Khozani T., Senanayake V., et al.
    A randomized controlled trial of the effects of flaxseed lignan complex on metabolic syndrome composite score and bone mineral in older adults.
    Appl Physiol Nutr Metabol. 2009; 34: 89-98
  24. Cassani R.S., Fassini P.G., Silvah J.H., Lima C.M., Marchini J.S.
    Impact of weight loss diet associated with flaxseed on inflammatory markers in men with cardiovascular risk factors: a clinical study.
    Nutr J. 2015; 14: 5
  25. Rodriguez-Leyva D., Weighell W., Edel A.L., LaVallee R., Dibrov E., Pinneker R., et al.
    Potent antihypertensive action of dietary flaxseed in hypertensive patients.
    Hypertension. 2013; 62: 1081-1089
  26. Dodin S., Lemay A., Jacques H., Legare F., Forest J.-C., Masse B.
    The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double-blind, wheat germ placebo-controlled clinical trial.
    J Clin Endocrinol Metabol. 2005; 90: 1390-1397
  27. Barceló-Coblijn G., Murphy E.J., Othman R., Moghadasian M.H., Kashour T., Friel J.K.
    Flaxseed oil and fish-oil capsule consumption alters human red blood cell n–3 fatty acid composition: a multiple-dosing trial comparing 2 sources of n–3 fatty acid.
    Am J Clin Nutr. 2008; 88: 801-809
  28. Hallund J., Tetens I., Bügel S., Tholstrup T., Ferrari M., Teerlink T., et al.
    Daily consumption for six weeks of a lignan complex isolated from flaxseed does not affect endothelial function in healthy postmenopausal women.
    J Nutr. 2006; 136: 2314-2318
    Scopus (30)
  29. Katare C., Saxena S.
    Amelioration of selected cardiac risk factors through supplementation of diet with flaxseed and soya bean.
    Int J Nutr Pharmacol Neurol Dis. 2013; 3: 352
  30. Machado A.M., de Paula H., Cardoso L.D., Costa N.M.
    Effects of brown and golden flaxseed on the lipid profile, glycemia, inflammatory biomarkers, blood pressure and body composition in overweight adolescents.
    Nutrition. 2015; 31: 90-96
  31. Pan A., Sun J., Chen Y., Ye X., Li H., Yu Z., et al.
    Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: a randomized, double-blind, cross-over trial.
    PloS One. 2007; 2: e1148
  32. Paschos G., Magkos F., Panagiotakos D., Votteas V., Zampelas A.
    Dietary supplementation with flaxseed oil lowers blood pressure in dyslipidaemic patients.
    Eur J Clin Nutr. 2007; 61: 1201-1206
  33. Saxena S., Katare C.
    Evaluation of flaxseed formulation as a potential therapeutic agent in mitigation of dyslipidemia.
    Biomed J. 2013; 37: 386-390
  34. Schwab U.S., Callaway J.C., Erkkilä A.T., Gynther J., Uusitupa M.I., Järvinen T.
    Effects of hempseed and flaxseed oils on the profile of serum lipids, serum total and lipoprotein lipid concentrations and haemostatic factors.
    Eur J Nutr. 2006; 45: 470-477
  35. Wu H., Pan A., Yu Z., Qi Q., Lu L., Zhang G., et al.
    Lifestyle counseling and supplementation with flaxseed or walnuts influence the management of metabolic syndrome.
    J Nutr. 2010; 140: 1937-1942
  36. Prasad K.
    Secoisolariciresinol diglucoside (SDG) isolated from flaxseed, an alternative to ACE inhibitors in the treatment of hypertension.
    Int J Angiol. 2013; 22: 235-238
  37. Lemos J.R., Alencastro M.G., Konrath A.V., Cargnin M., Manfro R.C.
    Flaxseed oil supplementation decreases C-reactive protein levels in chronic hemodialysis patients.
    Nutr Res. 2012; 32: 921-927
  38. Pan A., Demark-Wahnefried W., Ye X., Yu Z., Li H., Qi Q., et al.
    Effects of a flaxseed-derived lignan supplement on C-reactive protein, IL-6 and retinol-binding protein 4 in type 2 diabetic patients.
    Br J Nutr. 2009; 101: 1145-1149
  39. Doyen A., Udenigwe C.C., Mitchell P.L., Marette A., Aluko R.E., Bazinet L.
    Anti-diabetic and antihypertensive activities of two flaxseed protein hydrolysate fractions revealed following their simultaneous separation by electrodialysis with ultrafiltration membranes.
    Food Chem. 2014; 145: 66-76
  40. Nunes D.O., Almenara C.C., Broseghini-Filho G.B., Silva M.A., Stefanon I., Vassallo D.V., et al.
    Flaxseed oil increases aortic reactivity to phenylephrine through reactive oxygen species and the cyclooxygenase-2 pathway in rats.
    Lipids Health Dis. 2014; 13: 107
  41. Bassett C.M., Rodriguez-Leyva D., Pierce G.N.
    Experimental and clinical research findings on the cardiovascular benefits of consuming flaxseed.
    Appl Physiol Nutr Metabol. 2009; 34: 965-974
  42. Austria J.A., Richard M.N.,, Chahine M.N., Edel A.L., Malcolmson L.J., Dupasquier C.M., et al.
    Bioavailability of alpha-linolenic acid in subjects after ingestion of three different forms of flaxseed.
    J Am Coll Nutr. 2008; 27: 214-221
  43. Kristensen M., Jensen M.G., Aarestrup J., Petersen K., Søndergaard L., Mikkelsen M.S., et al.
    Flaxseed dietary fibers lower cholesterol and increase fecal fat excretion, but magnitude of effect depend on food type.
    Nutr Metabol. 2012; : 9
  44. Theuwissen E., Mensink R.P.
    Water-soluble dietary fibers and cardiovascular disease.
    Physiol Behav. 2008; 94: 285-292
  45. Kuijsten A., Arts I.C.W., Van’t Veer P., Hollman P.C.H.
    The relative bioavailability of enterolignans in humans is enhanced by milling and crushing of flaxseed.
    J Nutr. 2005; 135: 2812-2816
  46. Cunnane S.C., Ganguli S., Menard C., Liede A.C., Hamadeh M.J., Chen Z.-Y., et al.
    High α-linolenic acid flaxseed (Linum usitatissimum): some nutritional properties in humans.
    Br J Nutr. 1993; 69: 443-453
  47. Sleight P., Yusuf S., Pogue J., Tsuyuki R., Diaz R.
    Probstfield J.
    Blood-pressure reduction and cardiovascular risk in HOPE study.
    Lancet. 2001; 358: 2130-2131

© 2023 Lipid and Blood Pressure Meta-Analysis Collaboration Group All Rights Reserved

Site map